Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Equity Average (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Equity Average for 4 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 3.23% to $3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.4 million, a 3.23% increase, with the full-year FY2024 number at $3.7 million, down 53.09% from a year prior.
  • Equity Average was $3.4 million for Q3 2025 at bioAffinity Technologies, up from -$348352.0 in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $11.8 million in Q4 2022 to a low of -$16.8 million in Q2 2022.
  • A 4-year average of $3.3 million and a median of $3.9 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 460.38% in 2023, then tumbled 108.02% in 2025.
  • bioAffinity Technologies' Equity Average stood at $11.8 million in 2022, then crashed by 49.88% to $5.9 million in 2023, then tumbled by 51.7% to $2.9 million in 2024, then increased by 18.23% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Equity Average are $3.4 million (Q3 2025), -$348352.0 (Q2 2025), and $2.0 million (Q1 2025).